HighTower Advisors’s Twist Bioscience TWST Stock Holding History

HighTower Advisors’s Portfolio TWST Stock Details TWST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,686	Closed	-$287K	–	3692
2021 Q4	$287K	Buy	3,686 +435	+13%	+$44.6K	﹤0.01%	2497
2021 Q3	$348K	Buy	3,251 +1,339	+70%	+$153K	﹤0.01%	2318
2021 Q2	$255K	Buy	1,912 +263	+16%	+$30.6K	﹤0.01%	2484
2021 Q1	$201K	Buy	+1,649	New	+$250K	﹤0.01%	2600

Other funds holding TWST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HighTower Advisors's TWST Position: Q1 2022 in Review

HighTower Advisors sold out of Twist Bioscience (TWST) in Q1 2022, closing a stake of 3,686 shares — an estimated $287K sold.

HighTower Advisors first reported a position in TWST in Q1 2021 and held it in 4 quarters. The position peaked at $348K in Q3 2021. 212 funds tracked by Wall St. Rank hold TWST as of Q1 2022.

HighTower Advisors reported no remaining Twist Bioscience position as of Q1 2022 after selling out during the quarter.
HighTower Advisors sold 3,686 Twist Bioscience shares in Q1 2022, an estimated $287K.
HighTower Advisors first reported a position in Twist Bioscience in Q1 2021 and held it in 4 quarters.
HighTower Advisors's Twist Bioscience position peaked at $348K in Q3 2021.
212 funds tracked by Wall St. Rank held Twist Bioscience as of Q1 2022.

Based on HighTower Advisors's 13F filing for Q1 2022, filed 12 May 2022.